Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential tenofovir lead-in followed by peginterferon alfa-2a vs peginterferon alone in chronic hepatitis B
2014-000453-37Phase 3Active
- Sponsor
- Azienda Ospedaliero-Universitaria di Padova
- Start
- Sep 2014
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tenofovir disoproxil fumarate and interferon alfa in Chronic Hepatitis B (CHB) (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Padova. Primary endpoint: Sustained virological response rate. Started Sep 2014; status: active.
02
Drugs
tenofovir disoproxil fumarateinterferon alfa
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2014-000453-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000453-37.